Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Key facts

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Intervention

TQB2825 injection +R-CHOP regimen(drug)

Enrollment

90 target

Eligibility

18-80 years · All sexes

Timeline

2025 – 2026

Study locations (25)

• The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
• Maanshan People's Hospital, Ma’anshan, Anhui, China
• Beijing Cancer Hospital, Beijing, Beijing Municipality, China
• Fujian Cancer Hospital, Fuzhou, Fujian, China
• The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
• Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
• Liuzhou People's Hospital, Liuzhou, Guangxi, China
• Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
• Puyang Oilfield General Hospital, Puyang, Henan, China
• Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Hubei Cancer Hospital, Wuhan, Hubei, China
• Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
• The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
• Jiangxi Canser Hospital, Nanchang, Jiangxi, China
• +10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing
• RECRUITINGPHASE2NCT06554600
  A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →